Investors should monitor initiation of the pivotal cohort and subsequent biomarker data readouts as key catalysts; BEAM-302 is now on a clear regulatory path with potential for accelerated approval, making it a high-upside gene therapy candidate in a rare disease with high unmet need.
Price Chart
Executive Summary
Beam Therapeutics announced updated Phase 1/2 data for BEAM-302, a base-edited therapy for alpha-1 antitrypsin deficiency (AATD), showing durable correction of the genetic mutation, with 94% of circulating AAT being functional M-AAT and an 84% reduction in toxic Z-AAT at the 60 mg dose. The company selected 60 mg as the optimal dose and plans to initiate a global pivotal cohort in the second half of 2026 under an FDA-supported accelerated approval pathway based on biomarker endpoints.
Key Facts
- BEAM-302 achieved mean steady-state total AAT of 16.1 µM at 60 mg, with all patients above the 11 µM protective threshold
- Corrected M-AAT comprised 94% of total AAT; mutant Z-AAT reduced by 84% in the 60 mg cohort
- Safety profile was well-tolerated up to 75 mg, with no serious adverse events in single-dose cohorts
- FDA engagement supports accelerated approval based on 12-month AAT biomarker data
- Pivotal cohort expected to enroll ~50 additional patients, initiating in second half of 2026
Financial Impact
Potential near-term catalyst for accelerated approval; no direct revenue impact yet but de-risks clinical pathway
Risk Factors
- Pivotal trial delays or enrollment challenges
- Long-term safety or durability concerns beyond 18 months
- Regulatory requirement for confirmatory clinical outcomes post-approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $27.10 $23.22 | ▼ −14.32% | ▼ −12.34% | $24.33 (−10.22%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.79 $26.49 | ▼ −23.86% | ▼ −23.44% | $24.33 (−30.07%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.48 $26.02 | ▲ +22.28% | ▲ +20.10% | $24.33 (+27.33%) |
May 12, 2026 20w ago | Press Release | $31.58 $29.49 | ▼ −6.62% | ▼ −4.89% | $24.33 (−22.96%) |
Apr 17, 2026 23w ago | DEFA14A | $31.19 $26.81 | ▼ −14.04% | ▼ −18.25% | $24.33 (−21.99%) |
Mar 25, 2026 27w ago | Press Release | $23.12 $30.16 | ▲ +30.45% | ▲ +22.59% | $24.33 (+5.23%) |
Mar 5, 2026 30w ago | 8-K | $26.54 $24.23 | ▼ −8.70% | ▼ −6.66% | $24.33 (−8.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access